SIRPA and graft versus host disease: Finally, when used in vivo in a T-cell-dependent xeno-GvHD model mediated by the injection of human PBMC in NSG-recipient mice, the anti-SIRPα-γ mAb KWAR23 impairs human cell engraftment, leading to a delayed GvHD onset.